Research
Hormonal
GLP1R agonists (like liraglutide) suppress food intake by acting on LepRbGlp1r neurons, but this pathway alone is insufficient for significant body weight loss.
GLP-1 drugs like liraglutide work partly by activating a specific brain pathway (LepRbGlp1r) that tells you to eat less. However, this pathway alone doesn't account for all the weight loss, meaning other brain areas are also involved. This suggests these drugs are complex and work on multiple levels.
StrongQualifiesHIGH confidence
Restoration of Glp1r expression in LepRbGlp1r neurons in otherwise Glp1r-null mice enabled food intake suppression by the GLP1R agonist, liraglutide.
Why this rating
Clear genetic reactivation experiments showing causality.
Source
Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models
Alan C. Rupp et al. · Journal of Clinical Investigation · 2023
DOI 10.1172/jci157515
mechanism_onlyCited 53×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →